增持计划旨在巩固CCM的控股地位，提高CCM的持股比例，并向市场传递控股股东对集团未来前景及 长远发展充满信心的积极信息。 格隆汇9月12日丨美中嘉和(02453.HK)发布公告，公司获公司控股股东Concord Medical Services Holdings Limited("CCM")告知，CCM计划于本公告起计12个月内增持公司股权。公司已获告知，为进行增持， CCM将透过其附属公司以自有资金于公开市场进行增持，具体增持交易将根据规则及时披露。 ...

本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）自願刊發。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 控股股東擬增持股權 楊建宇 中國北京，2025年9月12日 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事王雷先生、宋清寶先生及施波濤先生；及(iii)獨立非執行董事李雪梅女 士、孫延生先生及吳國賢先生。 本公司獲本公司控股股東Concord Medical Services Holdings Limited（「CCM」）告 知，CCM計劃於本公告起計12個月內增持本公司股權。本公司已獲告知，為進行 增持，CCM將透過其附屬公司以自有資金於公開市場進行增持，具體增持交易將 根據規則及時披露。 增持計劃旨在鞏 ...

Core Insights - The report highlights significant changes in the stock holdings of various companies under the Hong Kong Stock Connect program, with notable increases and decreases in ownership percentages [1][2]. Group 1: Companies with Increased Holdings - China Merchants Energy (中远海能, 01138) saw the largest increase in holdings, up by 3.98% to a total holding of 64.59% [2]. - Country Garden (碧桂园, 02007) experienced a 1.24% increase, bringing its holding to 11.93% [2]. - Chifeng Jilong Gold Mining (赤峰黄金, 06693) increased by 1.09%, with a current holding of 45.70% [2]. - Other notable increases include Zhongxin Innovation (中创新航, 03931) at +1.07% and Horizon Robotics (地平线机器人-W, 09660) at +0.96% [2]. Group 2: Companies with Decreased Holdings - Yisou Technology (宜搜科技, 02550) experienced the largest decrease, down by 5.42% to a holding of 41.47% [2]. - Zhixing Technology (知行科技, 01274) saw a reduction of 3.19%, now holding 25.37% [2]. - Meizhong Jiahe (美中嘉和, 02453) decreased by 3.07%, with a current holding of 35.63% [2]. - Other significant decreases include Haotian International Construction Investment (昊天国际建投, 01341) at -2.57% and Guancheng Watch Jewelry (冠城鐘錶珠宝, 00256) at -2.04% [2]. Group 3: Five-Day Changes - Over the last five trading days, China Merchants Energy (中远海能, 01138) had the highest increase of 6.88%, reaching a holding of 64.59% [3]. - Yangtze Optical Fibre and Cable (长飞光纤光缆, 06869) increased by 6.31%, now at 61.31% [3]. - Ganfeng Lithium (赣锋鋰业, 01772) rose by 3.49%, with a holding of 36.23% [3]. - Significant decreases included Yisou Technology (宜搜科技, 02550) at -6.57% and Longpan Technology (龙蟠科技, 02465) at -4.63% [3]. Group 4: Twenty-Day Changes - In the last twenty days, Anjuke Food (安井食品, 02648) saw the largest increase of 12.18%, with a holding of 19.34% [4]. - Bluefocus Communication Group (蓝思科技, 06613) increased by 10.54%, now holding 14.86% [4]. - Longfly Optical Fibre and Cable (长飞光纤光缆, 06869) rose by 7.52%, reaching a holding of 61.31% [4]. - The largest decrease was seen in Hong Kong Broadband (香港宽频, 01310) at -9.74%, with a holding of 0.33% [4].

Core Viewpoint - The company, Meizhong Jiahe Medical Technology Development Group, has made significant advancements in artificial intelligence, developing a multi-modal intelligent system that disrupts traditional medical examination reporting, currently in trial use at partner institutions [2]. Group 1: Technological Advancements - The new intelligent system is based on a self-optimizing large model that integrates core AI technologies such as computer vision, natural language processing, and knowledge graphs, enabling multi-modal processing of medical images, text reports, and structured data [2]. - The multi-modal intelligent application focuses on core health scenarios, creating a complete service loop that includes clinical diagnostic support, personalized health reports, and comprehensive health management solutions [2][3]. Group 2: Competitive Advantage - Unlike some medical institutions that only possess medical data without R&D capabilities, the company has access to a vast amount of high-quality clinical case data and possesses core AI technology development capabilities, enhancing its competitiveness in the medical AI field [3]. - The dual advantage of "data + R&D" allows the company to adapt its models to complex diagnostic scenarios, laying a solid foundation for future scalable replication [3]. Group 3: Business Model and Market Potential - The multi-modal intelligent application addresses the pain point of scarce quality resources in grassroots healthcare, forming a clear profit loop by enabling B-end institutions to access top-tier diagnostic capabilities without significant equipment investment [3]. - The company’s model of "technology empowerment + light asset operation" significantly lowers the technical and financial barriers for grassroots institutions, tapping into a market estimated to exceed 100 billion [3]. Group 4: Revenue Generation and Growth - The C-end value is substantial, as patients can receive high-level health assessment services at grassroots institutions, enhancing convenience and driving the monetization of high-value health management services [4]. - The dual model of "B-end customer acquisition + C-end monetization" ensures stable short-term revenue while opening up long-term growth potential, becoming a key support for the company's performance increase [4]. Group 5: Strategic Positioning - The company has established a comprehensive capability system encompassing "data, algorithms, and scenarios" based on its self-developed multi-modal intelligent architecture [4]. - As the commercialization of medical AI approaches, the company's effective implementation is expected to accelerate the conversion of R&D investment into revenue, potentially creating a second growth curve beyond its main medical services [4].

Group 1 - The core viewpoint of the article indicates that Meizhong Jiahe (02453) experienced a significant decline in stock price, dropping over 5% and hitting a new low since its listing at 3.29 HKD [1] - The stock was removed from the Hong Kong Stock Connect eligible list, effective from September 8, as announced by the Shanghai and Shenzhen Stock Exchanges [1] - The current proportion of shares held through the Hong Kong Stock Connect for Meizhong Jiahe is still high at 38.22% [1] Group 2 - For the first half of 2025, Meizhong Jiahe reported revenue of approximately 200 million HKD, representing a year-on-year decrease of 8.3% [1] - The company recorded a loss attributable to shareholders of about 177 million HKD, which is a narrowing of 2.9% compared to the previous year [1]

Group 1 - The stock of Meizhong Jiahe (02453) fell over 5%, hitting a new low of 3.29 HKD during trading, and closed at 3.42 HKD with a trading volume of 23.75 million HKD [1] - The Shanghai and Shenzhen Stock Exchanges announced that Meizhong Jiahe has been removed from the Hong Kong Stock Connect list, effective from September 8 [1] - Currently, Meizhong Jiahe has a Hong Kong Stock Connect holding ratio of 38.22% [1] Group 2 - For the first half of 2025, Meizhong Jiahe reported revenue of approximately 200 million HKD, a year-on-year decrease of 8.3% [1] - The company recorded a loss attributable to shareholders of approximately 177 million HKD, which represents a year-on-year narrowing of 2.9% [1]

Group 1 - The company has made significant advancements in the artificial intelligence sector by developing an optimized large model that enables the creation of a self-evolving multi-modal intelligent health examination report system [3] - The new system utilizes top expert thinking chain models to continuously learn and update cutting-edge medical knowledge, analyzing various user health data to generate personalized health reports [2] - This innovation aims to reduce misdiagnosis and missed diagnosis rates while supporting real-time remote medical connections, ensuring that primary healthcare institutions can access analysis capabilities equivalent to top-tier hospitals [2][3] Group 2 - The transition from traditional health examinations to intelligent health examinations represents not only a technological improvement but also an industrial transformation, making each health examination data point a guide for precise health management [2]

Major Developments - Meizhong Jiahe (02453) has successfully constructed a self-evolving multimodal intelligent agent architecture, and the intelligent agent inspection report system has begun trial use [1] - Fuhong Hanlin (02696) received approval from the U.S. Food and Drug Administration for the clinical trial application of HLX17, a biosimilar of pembrolizumab, in patients with various resected solid tumors [1] - Xiansheng Pharmaceutical (02096) has received a clinical trial approval notice from the National Medical Products Administration for SIM0609, an antibody-drug conjugate targeting CDH17 [1] - Yuanda Pharmaceutical (00512) has received approval for a new indication in Europe for its globally innovative radioactive product SIR-Spheres® Yttrium-90 microsphere injection [1] Financial Data - Dongfeng Motor Corporation (00489) reported cumulative automobile sales of approximately 1.1386 million units in the first eight months, a year-on-year decrease of about 5.0% [1] - Dekang Agriculture and Animal Husbandry (02419) sold 813,100 pigs in August, generating sales revenue of 1.432 billion yuan [1] - Longyuan Power (00916) completed a cumulative power generation of 51.2546 million megawatt-hours in the first eight months, a year-on-year decrease of 0.001% [1] - New City Development (01030) reported a cumulative contract sales amount of approximately 13.566 billion yuan in the first eight months, a year-on-year decrease of 54.08% [1] - Qiu Tai Technology (01478) sold a total of 47.079 million camera modules in August, with a month-on-month increase of 18.4% and a year-on-year increase of 44.3% [1]

Core Viewpoint - The company has made significant advancements in the artificial intelligence sector by developing a self-evolving multimodal intelligent architecture, which has led to the creation of a revolutionary intelligent health examination report system that is currently being trialed in partner institutions [1] Group 1: Technological Advancements - The new system utilizes a top-tier expert thinking chain model that continuously learns and updates medical frontier knowledge in real-time [1] - It comprehensively analyzes multimodal data including user health examination images, tests, and medical history to generate personalized health reports [1] Group 2: Impact on Healthcare - The system significantly reduces misdiagnosis and missed diagnosis rates by eliminating human biases and accurately identifying complex health risks [1] - It supports real-time linkage with remote medical nodes, enabling expert-level report generation in seconds, thus providing grassroots institutions with access to tertiary hospital analytical capabilities [1] Group 3: Industry Transformation - The transition from traditional health examinations to intelligent health examinations represents not only a technological improvement but also an industrial transformation [1] - Each health examination data point becomes an intelligent guide for precise health management, enhancing the overall quality of healthcare delivery [1]

Core Viewpoint - The removal of certain stocks from the Hong Kong Stock Connect list has led to significant declines in their share prices, indicating a negative market reaction to the index adjustments [1] Group 1: Stock Performance - Yisou Technology (02550) experienced a drop of 31.53%, trading at HKD 3.17 [1] - Meizhong Jiahe (02453) fell by 25.32%, with a price of HKD 3.54 [1] - Guancheng Watch and Jewelry (00256) decreased by 22.71%, now at HKD 0.228 [1] - Sipai Health (00314) saw a decline of 13.6%, trading at HKD 4.7 [1] Group 2: Market Announcement - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced adjustments to the constituent stocks of the Hang Seng Composite Large, Mid, and Small Cap Indices, effective from September 8 [1] - A total of 20 stocks, including Yisou Technology, Meizhong Jiahe, Guancheng Watch and Jewelry, and Sipai Health, were removed from the Hong Kong Stock Connect eligible securities list [1]